Lisata Therapeutics, Inc. (LSTA)
NASDAQ: LSTA · Real-Time Price · USD
0.8989
-0.0111 (-1.22%)
At close: Nov 20, 2026, 4:00 PM EST
0.8800
-0.0189 (-2.10%)
After-hours: Nov 20, 2026, 7:45 PM EST
Lisata Therapeutics Employees
Lisata Therapeutics had 21 employees as of December 31, 2025. The number of employees decreased by 5 or 19.23% compared to the previous year. That makes Lisata Therapeutics the 38,220th largest employer in the world and 5,454th in the United States.
Employees
21
Change (1Y)
-5
Growth (1Y)
-19.23%
Revenue / Employee
$4,762
Profits / Employee
-$817,095
Market Cap
9.71M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 21 | -5 | -19.23% |
| Dec 31, 2024 | 26 | 1 | 4.00% |
| Dec 31, 2023 | 25 | -2 | -7.41% |
| Dec 31, 2022 | 27 | 0 | - |
| Dec 31, 2021 | 27 | 3 | 12.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 82 |
| Vistagen Therapeutics | 41 |
| BioLineRx | 24 |
| IN8bio | 20 |
| Moleculin Biotech | 17 |
| Radiopharm Theranostics | 14 |
| CalciMedica | 12 |
| Immuron | 8 |
LSTA News
- 2 days ago - Lisata Therapeutics announces one-for-fifteen reverse stock split - TheFly
- 2 days ago - Lisata Therapeutics, Inc. Announces Reverse Stock Split Effective November 23, 2026 - GlobeNewsWire
- 2 days ago - Lisata Therapeutics Registration statement: Registration filing - Filings
- 5 days ago - Lisata Therapeutics Transcript: Jefferies Global Healthcare Conference - Transcripts
- 8 days ago - Lisata Therapeutics Quarterly report: Q3 2026 - Filings
- 9 days ago - Lisata Therapeutics registers to sell 350.5M shares of common stock for holders - TheFly
- 11 days ago - Lisata Therapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 12 days ago - Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces MAR001 Reduces Triglycerides Without Worsening Glycemic Control in Phase 2b TYDAL-TIMI 78 Trial; Results Presented as AHA 2026 Late-Breaker and Published in The New England Journal of Medicine - GlobeNewsWire